| Product Unit Size | Cost | Quantity | Stock |
|---|
Azilsartan medoxomil is an angiotensin II receptor antagonist. It may provide a beneficial effect on the mechanisms involved in cardiometabolic disease and insulin sensitizing in cells. Diabetic mice treated with azilsartan had lowered expressions of pro-inflammatory cytokines in brain vessels and lowered diabetes-induced BBB permeability.
| Cas No. | 863031-21-4 |
|---|---|
| Purity | ≥98% |
| Formula | C30H24N4O8 |
| Formula Wt. | 568.54 |
| Chemical Name | 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
| IUPAC Name | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate |
| Synonym | TAK 491; TAK-491; TAK491 |
| Melting Point | 212-214 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Kurtz T, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-143. PMID: 22399858.
Han J, Tang H, Yao L, et al. Azilsartan protects against hyperglycemia-induced hyperpermeability of the blood-brain barrier. Bioengineered. 2021 Dec;12(1):3621-3633. PMID: 34266350.
Li W, Wang C, Zhang D, et al. Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2. Aging (Albany NY). 2021 May 4; 13(9):12996-13005. PMID: 33946046.
Baker W, White W. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011 Dec;45(12):1506-1515. PMID: 22116996.